Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$71K Buy
2,948
+23
+0.8% +$602 0.01% 224
2026
Q1
$82.1K Sell
2,925
-25,055
-90% -$667K 0.02% 227
2025
Q4
$697K Buy
27,980
+25,131
+882% +$634K 0.15% 152
2025
Q3
$72.6K Buy
2,849
+1,107
+64% +$27.3K 0.02% 233
2025
Q2
$42.2K Buy
1,742
+160
+10% +$3.73K 0.01% 253
2025
Q1
$40.1K Sell
1,582
-50
-3% -$1.31K 0.01% 237
2024
Q4
$43.3K Sell
1,632
-5
-0.3% -$136 0.01% 234
2024
Q3
$47.4K Buy
1,637
+18
+1% +$525 0.01% 233
2024
Q2
$45.3K Buy
1,619
+58
+4% +$1.6K 0.01% 235
2024
Q1
$43.3K Sell
1,561
-12,003
-88% -$333K 0.01% 231
2023
Q4
$391K Sell
13,564
-11,238
-45% -$340K 0.12% 174
2023
Q3
$823K Buy
24,802
+2,550
+11% +$90.2K 0.27% 118
2023
Q2
$816K Sell
22,252
-50
-0.2% -$1.95K 0.27% 123
2023
Q1
$910K Buy
22,302
+3,461
+18% +$149K 0.3% 98
2022
Q4
$965K Sell
18,841
-151
-0.8% -$7.24K 0.35% 88
2022
Q3
$832K Sell
18,992
-911
-5% -$44.3K 0.33% 93
2022
Q2
$1.04M Buy
19,903
+16,197
+437% +$825K 0.41% 79
2022
Q1
$192K Buy
3,706
+2,236
+152% +$116K 0.06% 190
2021
Q4
$87K Hold
1,470
0.03% 227
2021
Q3
$63K Hold
1,470
0.02% 241
2021
Q2
$58K Hold
1,470
0.02% 240
2021
Q1
$53K Sell
1,470
-22,303
-94% -$792K 0.02% 230
2020
Q4
$875K Sell
23,773
-826
-3% -$30.3K 0.36% 95
2020
Q3
$857K Buy
24,599
+21,571
+712% +$756K 0.4% 87
2020
Q2
$94K Hold
3,028
0.05% 157
2020
Q1
$94K Sell
3,028
-81
-3% -$2.76K 0.07% 148
2019
Q4
$116K Sell
3,109
-25,744
-89% -$917K 0.07% 150
2019
Q3
$655K Buy
28,853
+10,693
+59% +$389K 0.4% 85
2019
Q2
$746K Sell
18,160
-13,039
-42% -$518K 0.45% 66
2019
Q1
$1.26M Buy
31,199
+4,544
+17% +$182K 0.83% 36
2018
Q4
$1.1M Buy
26,655
+9,219
+53% +$383K 0.83% 36
2018
Q3
$729K Sell
17,436
-444
-2% -$17.1K 0.46% 65
2018
Q2
$615K Sell
17,880
-14,564
-45% -$498K 0.43% 75
2018
Q1
$1.08M Buy
32,444
+1,308
+4% +$45K 0.79% 38
2017
Q4
$1.07M Buy
+31,136
New +$1.06M 0.82% 37

Other funds holding PFE

NVWM LLC's PFE Position: Q2 2026 in Review

NVWM LLC increased its Pfizer (PFE) stake by 0.79% in Q2 2026, buying an estimated $602 and bringing the position to 2,948 shares worth $71K. The position accounts for 0.01% of the portfolio, ranked #224.

NVWM LLC first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.26M in Q1 2019. 1,425 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • NVWM LLC held 2,948 shares of Pfizer worth $71K as of Q2 2026.
  • NVWM LLC bought 23 Pfizer shares in Q2 2026, an estimated $602.
  • Pfizer made up 0.01% of NVWM LLC's portfolio in Q2 2026, its #224 holding.
  • NVWM LLC first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
  • NVWM LLC's Pfizer position peaked at $1.26M in Q1 2019.
  • 1,425 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on NVWM LLC's 13F filing for Q2 2026, filed 29 Jul 2026.